Oragenics Inc. reports developments as a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company’s lead candidate, ONP-002, is an investigational intranasal neurosteroid being evaluated for concussion and mild traumatic brain injury, with updates centered on clinical trial operations, regulatory clearances, site activity and dosing milestones.
Company news also covers annual-report disclosures, operating and financial results, capital-structure actions, material agreements, shareholder voting matters and governance updates. Oragenics’ communications frequently connect its CNS strategy, intranasal delivery platform and public-company reporting obligations as an NYSE American-listed biotechnology issuer.
Oragenics, Inc. (NYSE American: OGEN) has successfully closed its registered direct offering of 14,444,444 shares of common stock at $0.45 per share, raising gross proceeds of $6.5 million. The funds will primarily support the pre-clinical development of its Terra CoV-2 vaccine candidate, aimed at combating the coronavirus, as well as its lantibiotics program and general corporate initiatives. The shares were offered under a previously effective registration statement with the SEC.
Oragenics, Inc. (NYSE American: OGEN) has announced a registered direct offering of 14,444,444 shares of common stock at $0.45 per share, with closing expected on December 29, 2020. This offering is underpinned by an effective shelf registration statement filed with the SEC. A.G.P./Alliance Global Partners is the sole placement agent. The company is focused on developing the Terra CoV-2 vaccine candidate against COVID-19, leveraging NIH research. Investors are advised to review the forthcoming prospectus supplement for detailed information regarding the offering.